Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90

Oncogene

Volumn 35, Issue 2, 2016, Pages 261-268

  Zunino, B ^a,b,c   Rubio Patino C ^a,b   Villa, E ^a,b   Meynet, O ^a,b   Proics, E ^a,b   Cornille, A ^a,b   Pommier, S ^a,b,c   Mondragon L ^a,b   Chiche, J ^a,b   Bereder, J M ^c   Carles, M ^a,b,c   Ricci, J E ^a,b,c  

^a CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 90; MITOMYCIN; TANESPIMYCIN; CANCER VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARCINOMATOUS PERITONITIS; CELL DEATH; CELL MEMBRANE; CELL SURFACE; CONTROLLED STUDY; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR IMMUNITY; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; COCULTURE; DENDRITIC CELL; DRUG SCREENING; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MULTIMODALITY CANCER THERAPY; PERITONEAL NEOPLASMS; PROCEDURES; THERMOTHERAPY; TUMOR CELL LINE;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CELL MEMBRANE; COCULTURE TECHNIQUES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYPERTHERMIA, INDUCED; MICE, INBRED BALB C; PERITONEAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84954388087     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.82     Document Type: Article

References (26)

1. Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27:681-685.
2. Spiliotis JD. Peritoneal carcinomatosis cytoreductive surgery and HIPEC: a ray of hope for cure. Hepatogastroenterology 2010; 57: 1173-1177.
3. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31: 51-72.
4. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 2010; 1805: 53-71.
5. Lanneau D, Brunet M, Frisan E, Solary E, Fontenay M, Garrido C. Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med 2008; 12:743-761.
6. Murshid A, Gong J, Calderwood SK. The role of heat shock proteins in antigen cross presentation. Front Immunol 2012; 3: 63.
7. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007; 109 : 4839-4845.
8. Pockley AG. Heat shock proteins as regulators of the immune response. Lancet 2003; 362: 469-476.
9. Botzler C, Li G, Issels RD, Multhoff G. Definition of extracellular localized epitopes of Hsp70 involved in an NK immune response. Cell Stress Chaperones 1998; 3: 6-11.
10. Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337: 1678-1684.
11. Pelz JO, Vetterlein M, Grimmig T, Kerscher AG, Moll E, Lazariotou M et al. Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: role of heat shock proteins and dissecting effects of hyperthermia. Ann Surg Oncol 2013; 20: 1105-1113.
12. Tsutsumi S, Scroggins B, Koga F, Lee MJ, Trepel J, Felts S et al. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 2008; 27: 2478-2487.
13. Bae J, Mitsiades C, Tai YT, Bertheau R, Shammas M, Batchu RB et al. Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell. J Immunol 2007; 178: 7730-7737.
14. Schmitt E, Maingret L, Puig PE, Rerole AL, Ghiringhelli F, Hammann A et al. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res 2006; 66: 4191-4197.
15. Massey AJ, Williamson DS, Browne H, Murray JB, Dokurno P, Shaw T et al. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemother Pharmacol 2010; 66: 535-545.
16. Wilke CM, Wu K, Zhao E, Wang G, Zou W. Prognostic significance of regulatory T cells in tumor. Int J Cancer 2010; 127: 748-758.
17. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715-727.
18. Klaver YL, Hendriks T, Lomme RM, Rutten HJ, Bleichrodt RP, de Hingh IH. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery for peritoneal carcinomatosis in an experimental model. Br J Surg 2010; 97: 1874-1880.
19. Yang XJ, Li Y, al-shammaa Hassan AH, Yang GL, Liu SY, Lu YL et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. Ann Surg Oncol 2009; 16: 345-351.
20. Castellino F, Boucher PE, Eichelberg K, Mayhew M, Rothman JE, Houghton AN et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med 2000; 191: 1957-1964.
21. John K, Schreiber S, Kubelt J, Herrmann A, Muller P. Transbilayer movement of phospholipids at the main phase transition of lipid membranes: implications for rapid flip-flop in biological membranes. Biophys J 2002; 83: 3315-3323.
22. Tsvetkova NM, Horvath I, Torok Z, Wolkers WF, Balogi Z, Shigapova N et al. Small heat-shock proteins regulate membrane lipid polymorphism. Proc Natl Acad Sci USA 2002; 99: 13504-13509.
23. Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, Neckers L et al. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 2009; 9: 1479-1492.
24. Beneteau M, Zunino B, Jacquin MA, Meynet O, Chiche J, Pradelli LA et al. Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response. Proc Natl Acad Sci USA 2012; 109: 20071-20076.
25. Sugarbaker PH, Chang D, Stuart OA. Hyperthermic intraoperative thoracoabdominal chemotherapy. Gastroenterol Res Prac 2012; 2012: 623417.
26. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P et al. Consensus guidelines for the detection of immunogenic cell death. OncoImmunology 2014; 3: e955691.